Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 12, 2012, Pages

  Alazzam, Mo'iad ^a   Tidy, John ^b   Osborne, Raymond ^c   Coleman, Robert ^d   Hancock, Barry W ^d   Lawrie, Theresa A ^e  

^a Galway Clinic   (Ireland)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e ROYAL UNITED HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG RESISTANCE; FEMALE; HUMAN; PREGNANCY; REVIEW; TROPHOBLASTIC TUMOR; TUMOR RECURRENCE;

DRUG RESISTANCE, NEOPLASM; FEMALE; GESTATIONAL TROPHOBLASTIC DISEASE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PREGNANCY;

EID: 84874161014     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008891.pub2     Document Type: Review

References (63)

1. Alazzam M, Tidy J, Hancock BW, Osborne R. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD007102.pub3]
2. Azab M, Droz JP, Theodore C, WolffJP, Amiel JL. Cisplatin, vinblastine and bleomycin combination in the treatment of resistant high risk gestational trophoblastic tumors. Cancer 1989;64:1829-32.
3. Bagshawe KD. Risk and prognostic factors in trophoblastic neoplasia. Cancer 1976;38(3):1373-85.
4. Covens A, Fialici VL, Burger RA, Osborne R, Chen MD. Phase II. trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia. Cancer 2006;107(6):1280-6.
5. Common Terminology Criteria for Adverse Events (CTCAE), V 4.0, 2010. National Cancer Institute. evs.nci.nih.gov/ftp1/CTCAE/About.html. (accessed 19 October 2012).
6. Curry SL, Blessing JA, DiSaia PJ, Soper JT, Twiggs LB. A prospective randomised comparison of methotrexate, dactinomycin and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea and vincristine in 'poor prognosis' metastatic gestational trophoblastic disease: a Gynaecologic Oncology Group study. Obstetrics & Gynecology 1989;73(3, Part 1):357-62.
7. Cyriac S, Rajendranath R, Sridevi V, Sagar TG. Etoposide, cisplatin-etoposide, methotrexate, actinomycin-D as primary treatment for management of very-high-risk gestational trophoblastic neoplasia. International Journal of Gynaecology and Obstetrics 2011;115(1):37-9.
8. Deng L, Yan X, Zhang J, Wu T. Combination chemotherapy for high-risk gestational trophoblastic tumour. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD005196.pub3]
9. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
10. Dobson LS, Lorigan PC, Coleman RE, Hancock BW. Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease. British Journal of Cancer 2000;82:1547-52.
11. El-Helw LM, Seckl MJ, Haynes R, Evans LS, Lorigan PC, Long J, et al. High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia. British Journal of Cancer 2005;93:620-1.
12. El-Helw LM, Coleman RE, Everard JE, Tidy JA, Horsman JM, Elkhenini HF, et al. Impact of the revised FIGO/WHO system on the management of patients with gestational trophoblastic neoplasia. Gynecologic Oncology 2009;113(3):306-11.
13. Feng F, Xiang Y, Wan X, Geng S, Wang T. Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia. Annals of Oncology 2011;22:1588-94.
14. FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary and gestational trophoblastic neoplasia. International Journal of Gynaecology and Obstetrics 2009;105:3-4.
15. Ghaemmaghami F, Modares M, Arab M, Behtash N, Moosavi AZ, Khanafshar N, et al. EMA-EP regimen, as first line multiple agent chemotherapy in high-risk GTT patients (stage II-IV). International Journal of Gynecological Cancer 2004;14(2):360-5.
16. Goldstein DP, Berkowitz RS. Current management of gestational trophoblastic neoplasia. Hematology and Oncology Clinics of North America 2012;26:111-131.
17. Hammond CB, Borchert LG, Tyrey L, Creaman WT, Parker RT. Treatment of metastatic trophoblastic disease: good and poor prognosis. American Journal of Obstetrics and Gynecology 1973;115(4):451-7.
18. Hancock BW, Nazir K, Everard JE. Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome. Journal of Reproductive Medicine 2006;51:764-6.
19. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
20. Homeseley HD, Blessing JA, Rettenmaier M, Capizzi RL, Major FJ, Twiggs LB. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstetrics and Gynecology 1988;72(3):413-8.
21. Homesley HD, Hancock BW. Chapter 13: Treatment of non-metastatic gestational trophoblastic disease. Gestational Trophoblastic Disease. 3rd Edition. ISSTD: International Society for the Study of Trophoblastic Diseases, 2009:366-79.
22. Khan F, Everard J, Ahmed S, Coleman RE, Aitkin M, Hancock BW. Low-risk persistent trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long term effects. British Journal of Cancer 2003;89(12):2197-201.
23. Kim SJ, Bae SN, Kim JH, Kim CJ, Jung JK. Risk factors for the prediction of treatment failure in gestational trophoblastic tumours treated with the EMA/CO regimen. Gynecologic Oncology 1998;71:247-53.
24. Kohorn EI, Goldstein DP, Hancock BW, Kim SJ, Lurain JR, Newlands E, et al. Combining the staging system of the International Federation of Gynecology and Obstetrics with the scoring system of the World Health Organization for trophoblastic neoplasia. Report of the Working Committee of the International Society for the Study of Trophoblastic Disease and International Gynecologic Cancer Society. International Journal of Gynecological Cancer 2000;10:84-8.
25. Lee C, Smith HO, Kim SJ. Epidemiology. In: Hancock BW, Newlands ES, Berkowitz RS, Cole LA editor(s). Chapter 3: Gestational trophoblastic disease, International Society for the Study of Trophoblastic Diseases. 3rd Edition. ISSTD, 2009:49-96.
26. Lertkhachonsuk AA, Israngura N, Wilailak S, Tangtrakul S. Actinomycin d versus methotrexate-folinic acid as the treatment of stage I, low-risk gestational trophoblastic neoplasia: a randomized controlled trial. International Journal of Gynecological Cancer 2009;19(5):985-8.
27. Lu WG, Ye F, Shen YM, Fu YF, Chen HZ, Wan XY, et al. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients. International Journal of Gynaecological Cancer 2008;18(2):357-62.
28. Lurain JR, Elfstrand EP. Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors. American Journal of Obstetrics and Gynaecology 1995;172:574-9.
29. Lurain J, Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. Gynecologic Oncology 2005;97:618-23.
30. Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. American Journal of Obstetrics & Gynecology 2010;203(6):531-9.
31. Lurain JR, Singh DK, Schink JC. Management of metastatic high-risk gestational trophoblastic neoplasia: FIGO stages II-IV: risk factor score > or = 7. Journal of Reproductive Medicine 2010;55(5-6):199-207.
32. Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. American Journal of Obstetrics & Gynecology 2011;204(1):11-8.
33. Manopunya M, Suprasert P. Resistant gestational trophoblastic neoplasia patients treated with 5-fluorouracil plus actinomycin D. Asian Pacific Journal of Cancer Prevention 2012;13(1):387-90.
34. Mao Y, Wan X, Lv W, Xie X. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen. International Journal of Gynaecology and Obstetrics 2007;98(1):44-7.
35. Matsui H, Suzuka K, Iitsuka Y, Yamazawa K, Tanaka N, Mitsuhashi A, et al. Salvage combination chemotherapy with 5-fluorouracil and actinomycin D for patients with refractory, high-risk gestational trophoblastic tumors. Cancer 2002;95(5):1051-4.
36. Matsui H, Iitsuka Y, Suzuka K, Yamazawa K, Mitsuhashi A, Sekiya S. Salvage chemotherapy for high-risk gestational trophoblastic tumor. Journal of Reproductive Medicine 2004;49(6):438-42.
37. Matsui H, Suzuka K, Yamazawa K, Tanaka N, Mitsuhashi A, Seki K, et al. Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy. Gynecologic Oncology 2005;96:616-20.
38. May T, Goldstein DP, Berkowitz RS. Current chemotherapeutic management of patients with gestational trophoblastic neoplasia: review article. Chemotherapy Research and Practice 2011;2011:806256.
39. McGrath S, Short D, Harvey R, Schmid P, Savage PM, Seckl MJ. The management and outcome of women with post-hydatidiform mole low-risk gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU/L1. British Journal of Cancer 2010;102(5):810-4.
40. McNeish IA, Strickland S, Holden L, Rustin GJ, Foskett M, Seckl MJ, et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. Journal of Clinical Oncology 2002;20(7):1838-44.
41. Nagan HY. The FIGO staging for gestational trophoblastic neoplasia 2000, FIGO Committee Report. International Journal of Gynecology and Obstetrics 2002;77:285-7.
42. Schink JC, DiSaia PJ and the Gynecologic Oncology Group. Methotrexate or dactinomycin in treating patients with low-risk gestational trophoblastic neoplasia. www.clinicaltrials.gov/ct2/show/NCT01535053 (accessed 19 October 2012).
43. Newlands ES, Bagshawe KD, Begent RH, Rustin GJ, Holden L, Dent J. Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979-1984). British Journal of Obstetrics and Gynaecology 1986;93(1):63-9.
44. Newlands ES, Mulholland PJ, Holden L, Seckl MJ, Rustin GJ. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. Journal of Clinical Oncology 2000;18:854-9.
45. Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, et al. Phase III. trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2011;29(7):825-31.
46. Palmer JR. Advances in the epidemiology of gestational trophoblastic disease. Journal of Reproductive Medicine 1994;39(3):155-62.
47. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
48. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
49. Rodriguez N, Goldstein DP, Berkowitz RS. Treating gestational trophoblastic disease. Expert Opinion in Pharmacotherapy 2010;11(18):3027-39.
50. Sebire NJ, Foskett M, Fisher RA, Rees H, Seckl M, Newlands E. Risk of partial and complete hydatidiform molar pregnancy in relation to maternal age. British Journal of Obstetrics and Gynaecology 2002;109:99-102.
51. Seckl MJ. Presentation and management of persistent gestational trophoblastic disease (GTD) and gestational trophoblastic tumours (GTT) in the United Kingdom. In: Hancock BW, Seckl M, Berkowitz RS, Cole LA editor(s). Gestational Trophoblastic Disease. 3rd Edition. London: International Society for the Study of Trophoblastic Diseases, 2009:277-98.
52. Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet 2010;376:717-29.
53. Song HZ, Yang XY, Xiang Y. Forty-five year's experience of the treatment of choriocarcinoma and invasive mole. International Journal of Gynaecology and Obstetrics 1998;60(Suppl 1):S77-83.
54. Soper JT, Evans AC, Rodriguez G, Berchuck A, Clarke-Pearson DL, Hammond CB. Etoposide-platin combination therapy for chemorefractory gestational trophoblastic disease. Gynecologic Oncology 1995;56(3):421-4.
55. Tham BW, Everard JE, Tidy JA, Drew D, Hancock BW. Gestational trophoblastic disease in the Asian population of Northern England and North Wales. British Journal of Obstetrics and Gynaecology 2003;110(6):555-9.
56. Theodore C, Azab M, Droz JP, Assouline A, George M, Piot G, et al. Treatment of high risk gestational trophoblastic disease with chemotherapy combinations containing cisplatin and etoposide. Cancer 1989;64:1824-8.
57. Wan X, Xiang Y, Yang X, Wu Y, Liu N, Chen L, et al. Efficacy of the FAEV regimen in the treatment of high-risk, drug-resistant gestational trophoblastic tumor. Journal of Reproductive Medicine 2007;52(10):941-4.
58. Wang S, An R, Han X, Zhu K, Xue Y. Combination chemotherapy with 5-fluorouracil, methotrexate and etoposide for patients with high-risk gestational trophoblastic tumors: a report based on our 11-year clinical experiences. Gynecologic Oncology 2006;103(3):1105-8.
59. Wang J, Short D, Sebire NJ, Lindsay I, Newlands ES, Schmid P, et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Annals of Oncology 2008;19:1578-3.
60. World Health Organization. Gestational trophoblastic diseases, 1983. apps.who.int/iris/handle/10665/39169. (accessed 19 October 2012).
61. Xiang Y, Sun Z, Wan X, Yang X. EMA/EP chemotherapy for chemo-refractory gestational trophoblastic tumor. Journal of Reproductive Medicine 2004;49(6):443-6.
62. Yarandi F, Eftekhar Z, Shojaei H, Kanani S, SharifiA, Hanjani P. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia. International Journal of Gynecology and Obstetrics 2008;103(1):33-7.
63. Zhao Y, Zhang W, Duan W. Management of gestational trophoblastic neoplasia with 5-fluorouracil and actinomycin D in northern China. Journal of Reproductive Medicine 2009;54(2):88-94.